Linden Thomas Advisory Services
LGND icon

Linden Thomas Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Linden Thomas Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.1M Sell
9,923
-12
-0.1% -$3.55K 0.25% 119
2026
Q2 		$3.14M Sell
9,935
-6,734
-40% -$1.59M 0.25% 117
2026
Q1 		$3.33M Buy
16,669
+94
+0.6% +$18.6K 0.32% 86
2025
Q4 		$3.13M Sell
16,575
-231
-1% -$44.4K 0.32% 85
2025
Q3 		$2.98M Buy
16,806
+14
+0.1% +$2.08K 0.3% 86
2025
Q2 		$1.91M Sell
16,792
-167
-1% -$17.8K 0.21% 152
2025
Q1 		$1.78M Sell
16,959
-49
-0.3% -$5.54K 0.23% 149
2024
Q4 		$1.82M Sell
17,008
-20
-0.1% -$2.26K 0.23% 148
2024
Q3 		$1.7M Sell
17,028
-84
-0.5% -$8.46K 0.23% 162
2024
Q2 		$1.44M Buy
17,112
+271
+2% +$21.6K 0.22% 187
2024
Q1 		$1.23M Buy
16,841
+448
+3% +$33K 0.2% 219
2023
Q4 		$1.17M Sell
16,393
-386
-2% -$22.8K 0.22% 200
2023
Q3 		$1.01M Sell
16,779
-29
-0.2% -$1.91K 0.22% 200
2023
Q2 		$1.21M Buy
+16,808
New +$1.26M 0.27% 149

Other funds holding LGND

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Linden Thomas Advisory Services's LGND Position: Q3 2026 in Review

Linden Thomas Advisory Services reduced its Ligand Pharmaceuticals (LGND) stake by 0.12% in Q3 2026, selling an estimated $3.55K and leaving 9,923 shares worth $3.1M. The position accounts for 0.25% of the portfolio, ranked #119.

Linden Thomas Advisory Services first reported a position in LGND in Q2 2023 and has held it in 14 quarters since. The position peaked at $3.33M in Q1 2026. 348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Linden Thomas Advisory Services held 9,923 shares of Ligand Pharmaceuticals worth $3.1M as of Q3 2026.
  • Linden Thomas Advisory Services sold 12 Ligand Pharmaceuticals shares in Q3 2026, an estimated $3.55K.
  • Ligand Pharmaceuticals made up 0.25% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #119 holding.
  • Linden Thomas Advisory Services first reported a position in Ligand Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
  • Linden Thomas Advisory Services's Ligand Pharmaceuticals position peaked at $3.33M in Q1 2026.
  • 348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.